Overall, these results indicate that BET inhibitor I-BET762 and PARP inhibitors have a preferential or selective combinatorial efficacy on MYCs-amplified or MYCs-wt SCLC cells over non-tumor cells or SCLC cells with an impaired MYC signaling pathway. This evidence concerns the gene PARP1 and neoplasm.